|
Jul 25
|
TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)
|
|
Jul 25
|
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
|
|
Jul 16
|
Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum
|
|
Jul 15
|
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
|
|
Jul 1
|
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
|
|
Jun 27
|
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
|
|
Feb 20
|
EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN
|
|
Feb 20
|
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
|